Last Updated: November 16, 2026

REBYOTA Drug Profile

« Back to Dashboard


Summary for Tradename: REBYOTA
High Confidence Patents:6
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for REBYOTA
Recent Clinical Trials for REBYOTA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Ferring PharmaceuticalsPhase 3

See all REBYOTA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for REBYOTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for REBYOTA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 12,036,250 2043-03-30 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 12,083,150 2042-12-07 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 12,102,655 2044-04-10 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 9,433,651 2034-06-30 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 9,675,648 2034-06-04 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 9,782,445 2035-05-08 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for REBYOTA Derived from Patent Text Search

No patents found based on company disclosures

Rebyota Market Dynamics and Financial Trajectory

Last updated: November 2, 2026

Rebyota is the first FDA-approved fecal microbiota product and the first commercial entrant in microbiome-based therapy. Ferring Pharmaceuticals markets Rebyota in the United States for preventing recurrent Clostridioides difficile infection in adults after antibacterial treatment. Its commercial trajectory depends on physician adoption, payer coverage, administration logistics and competition from Vowst, an oral microbiota product. Ferring has not publicly disclosed standalone Rebyota revenue, unit sales or profitability, limiting precise financial modeling.

What is Rebyota and what is its FDA status?

Rebyota is fecal microbiota, live-jslm, formerly identified as RBX2660. It is administered rectally as a single 150 mL dose after completion of antibacterial treatment for recurrent C. difficile infection.

The FDA approved Rebyota on November 30, 2022, under Biologics License Application No. 213846. The product is manufactured and commercialized by Ferring Pharmaceuticals through its Rebiotix business. The approved indication is prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent infection. Rebyota is not approved to treat active C. difficile infection.[1]

Category Rebyota status
Active product Fecal microbiota, live-jslm
Former development code RBX2660
FDA approval November 30, 2022
FDA application BLA 213846
Dosage form Rectal suspension
Administration One 150 mL dose
Target population Adults with recurrent C. difficile infection
Manufacturer Rebiotix, a Ferring Pharmaceuticals company
Commercial launch United States, 2023
Primary competitor Vowst, fecal microbiota spores, live-brpk
Regulatory category Biological product

Rebyota received a standard FDA approval rather than an accelerated approval. The FDA based approval on clinical evidence showing reduced recurrence compared with placebo in adults at elevated risk of recurrent infection.[1]

How large is the Rebyota market?

The addressable market is narrower than the overall C. difficile treatment market. Rebyota is used after recurrent infection and antibacterial therapy, not as a first-line treatment for initial infection.

The commercial opportunity is shaped by four factors:

  1. Recurrent C. difficile infection creates a clinically defined population with high hospitalization and retreatment costs.
  2. Existing standard-of-care antibiotics, including vancomycin and fidaxomicin, do not directly replace microbiota restoration.
  3. Rebyota requires healthcare-site administration, which adds operational friction.
  4. Vowst offers oral administration and competes directly for the same recurrence-prevention population.

The U.S. market has favorable clinical economics because recurrent C. difficile can lead to repeated antibiotic courses, emergency care and hospitalization. A microbiota product can be economically attractive to payers if it reduces recurrence, even at a substantial acquisition price. Actual uptake depends on whether insurers reimburse the product and administration fee without prior authorization barriers.

What is Rebyota’s commercial positioning?

Rebyota has three principal positioning advantages:

  • It was the first FDA-approved microbiota product.
  • It has an established regulatory and clinical record in recurrent C. difficile infection.
  • It is backed by Ferring, a global specialty pharmaceutical company with commercial infrastructure in gastroenterology and hospital medicine.

Its principal disadvantages are rectal delivery, reliance on healthcare professionals for administration and the absence of the convenience associated with oral products.

Rebyota is likely to be most competitive in hospitals, outpatient infusion or procedure centers and systems that already manage recurrent C. difficile through infectious-disease and gastroenterology programs.

What is Rebyota’s financial trajectory?

Ferring does not report Rebyota as a separately listed public-company product. Ferring Pharmaceuticals is privately held and does not provide the level of product-level revenue disclosure available from public companies such as Pfizer, Merck or AbbVie.

As a result, the following metrics are not publicly established in audited filings:

Financial metric Public disclosure status
Annual Rebyota revenue Not separately disclosed
Quarterly revenue Not separately disclosed
Net price Not consistently disclosed
Gross margin Not disclosed
Patient volume Not disclosed
Contribution profit Not disclosed
Sales and marketing expense Not disclosed
Product-level guidance Not disclosed

The financial trajectory can therefore be assessed through commercial milestones rather than reported revenue.

Rebyota financial milestones

Period Commercial or regulatory event Financial implication
2018 Ferring acquired Rebiotix Ferring assumed development and commercialization investment
2022 FDA approved Rebyota Converted development asset into commercial biologic
2023 U.S. commercial launch Initiated sales, market access and provider education
2023 onward Vowst entered the U.S. market Introduced direct competition and price-pressure risk
2024 onward Expansion of payer and provider adoption Determines whether product revenue scales beyond early adopters

The likely financial pattern is a slow initial ramp followed by a reimbursement-driven adoption curve. Rebyota is administered in a controlled clinical setting, so early sales depend on building treatment pathways rather than relying on ordinary retail pharmacy demand.

The product may produce strategic value for Ferring even before reaching blockbuster scale. It gives the company an early position in microbiome therapeutics and may support future products in inflammatory, infectious or gastrointestinal disease.

How does Rebyota compare with Vowst?

Vowst is the closest commercial substitute. The FDA approved Vowst, fecal microbiota spores, live-brpk, on April 26, 2023, for preventing recurrence of C. difficile infection in adults following antibacterial treatment for recurrent infection.[2]

Attribute Rebyota Vowst
Active product Fecal microbiota, live-jslm Fecal microbiota spores, live-brpk
Delivery Rectal suspension Oral capsules
FDA approval November 30, 2022 April 26, 2023
Developer Rebiotix/Ferring Seres Therapeutics
Current commercial owner Ferring Nestlé Health Science acquired Seres in 2024
Treatment setting Clinic or healthcare facility Oral outpatient administration
Key advantage First approved microbiota product and clinical experience Convenience and no rectal administration
Key risk Administration burden Newer commercial and ownership history
Competitive overlap High High

Vowst’s oral route is commercially important. It can reduce provider-administered treatment requirements and may simplify distribution through specialty pharmacy channels. Rebyota can counter with physician familiarity, its earlier approval and possible preference among providers who favor a directly administered product.

The competitive outcome is likely to depend less on regulatory differentiation than on payer coverage, contracting, treatment-center workflow and patient preference.

What is the Rebyota patent and exclusivity position?

Rebyota does not have a conventional small-molecule Orange Book exclusivity profile. The product is regulated as a biologic, so its key regulatory protections arise through the biologics framework rather than standard Hatch-Waxman listing.

Is Rebyota listed in the Orange Book?

No conventional Orange Book patent strategy should be expected for Rebyota. The FDA Orange Book primarily lists approved drug products and patent information under the drug-approval framework. Biologics approved under a BLA are generally tracked through the Purple Book rather than the Orange Book.[3]

The relevant competitive pathway is therefore a biosimilar or interchangeable biologic pathway, subject to the product’s regulatory classification and the FDA’s treatment of a complex, donor-derived microbiota product.

When does Rebyota lose biologic exclusivity?

The Biologics Price Competition and Innovation Act generally provides 12 years of reference-product exclusivity for eligible biologics, subject to statutory rules and FDA determinations. If the standard period applies from Rebyota’s 2022 approval, the relevant regulatory exclusivity window could extend into 2034. The exact competitive date depends on FDA reference-product treatment and any applicable exclusivity determinations.[4]

That exclusivity period does not eliminate all commercial competition. Vowst is a separately approved product, not a biosimilar to Rebyota. Competitors also may develop other microbiota-based products without relying on Rebyota’s approval.

What formulation and manufacturing barriers protect Rebyota?

The principal barriers are technical and operational:

  • Donor screening and qualification
  • Pathogen testing and release procedures
  • Microbiota collection and processing
  • Product consistency across donor material
  • Stability and storage requirements
  • Manufacturing controls for a complex biological mixture
  • Clinical evidence demonstrating recurrence reduction
  • Provider and payer acceptance

These barriers may be more commercially important than a single composition patent. Microbiota products are difficult to characterize using the same analytical framework applied to conventional drugs because the product contains a complex community of microorganisms.

Ferring and Rebiotix may hold patents covering manufacturing, processing, donor material, formulation, administration and methods of preventing recurrent infection. A definitive patent-by-patent freedom-to-operate assessment requires review of current U.S. and international patent records and claim status. Public FDA approval materials do not establish the complete enforceable patent estate.

Are there Paragraph IV challenges to Rebyota?

A conventional Paragraph IV challenge is not the primary expected pathway for Rebyota because Paragraph IV litigation is associated with Abbreviated New Drug Applications under the Hatch-Waxman Act. Rebyota is a biologic approved through a BLA.

Potential competition is more likely to arise through:

  • A biosimilar application, if FDA determines the product is eligible for that pathway
  • A separately developed microbiota product
  • An oral or capsule-based microbiota therapy
  • A live biotherapeutic product with a different manufacturing platform
  • Non-FDA-regulated fecal microbiota transplantation in permitted clinical settings

No publicly established Paragraph IV litigation against Rebyota is identified in the core FDA approval record. That does not eliminate future patent disputes involving manufacturing methods, formulations or methods of use.

What litigation and settlement risks affect Rebyota?

The principal legal risks are regulatory classification, patent scope, manufacturing reproducibility and competition from alternative microbiome products.

There is no established public settlement framework comparable to major small-molecule generic settlements. Because Rebyota is not principally exposed to ordinary ANDA competition, commercial litigation risk is more likely to involve:

  • Patent infringement claims against a competing microbiota product
  • Trade-secret or manufacturing-process disputes
  • Contract disputes involving donor material or manufacturing
  • Product-liability claims
  • Challenges involving advertising, reimbursement or medical claims
  • Disputes over biosimilar or follow-on biologic eligibility

The absence of a known major Rebyota patent settlement reduces near-term legal visibility but does not remove long-term freedom-to-operate risk.

How does Rebyota’s geographic coverage affect growth?

Rebyota’s strongest commercial opportunity is the United States because the FDA created the first clear approval pathway for a standardized microbiota product. Geographic expansion is more complex.

Region Commercial position
United States FDA-approved and commercially marketed
European Union Requires separate regulatory authorization and country-level reimbursement
United Kingdom Requires separate regulatory review and National Health Service adoption
Japan Requires local regulatory and clinical strategy
Canada Requires Health Canada authorization and payer access
Other markets Dependent on local classification of fecal microbiota products

Ferring’s global infrastructure supports expansion, but reimbursement and regulatory classification vary by country. Some jurisdictions treat microbiota products as biological medicines, while others have historically regulated fecal microbiota transplantation through medical, tissue or controlled clinical frameworks.

What generic entry risks exist for Rebyota?

Near-term generic substitution risk is low relative to conventional drugs. The more significant threat is product substitution.

High-risk competitive events

  1. Broader adoption of Vowst because of oral administration.
  2. Development of lower-cost microbiota products.
  3. Expansion of live biotherapeutic products with defined microbial strains.
  4. Payer policies that favor one microbiota product over another.
  5. Provider reluctance to establish rectal administration workflows.
  6. Improved antibiotic or antibody strategies that reduce the need for microbiota restoration.

Low-risk events

  • Immediate conventional generic substitution
  • Automatic pharmacy substitution
  • Short-term erosion from an ANDA filer
  • Direct biosimilar competition before regulatory and manufacturing standards mature

Rebyota’s economic protection therefore depends on clinical differentiation, manufacturing scale and payer contracts as much as on statutory exclusivity.

How strong is the Rebyota commercial position?

Rebyota has a strong first-mover position but a moderate commercial moat.

Factor Assessment Rationale
FDA status Strong First FDA-approved product in its class
Clinical need Strong Recurrent C. difficile has substantial morbidity and cost
Route of administration Moderate to weak Rectal delivery creates operational friction
Competitive intensity Moderate to high Vowst is a direct approved competitor
Patent visibility Unclear Biologic and process protection is more complex than Orange Book protection
Manufacturing barrier Strong Donor screening and product consistency are difficult
Payer leverage Uncertain Coverage determines practical treatment volume
Revenue transparency Weak Ferring does not disclose standalone product sales
Long-term differentiation Moderate Depends on outcomes, convenience and real-world evidence

Key Takeaways

  • Rebyota is FDA-approved fecal microbiota, live-jslm, for preventing recurrent C. difficile infection in adults after antibacterial treatment.
  • Ferring Pharmaceuticals owns the commercial opportunity through its Rebiotix business.
  • The product launched in a new market with no mature historical revenue benchmark.
  • Ferring has not publicly disclosed standalone Rebyota revenue, units, margins or product-level guidance.
  • Vowst is the principal competitor and has an important convenience advantage because it is administered orally.
  • Rebyota faces low conventional generic risk but meaningful substitution risk from oral microbiota products and live biotherapeutics.
  • Orange Book and Paragraph IV mechanisms are less central because Rebyota is a biologic approved under a BLA.
  • Manufacturing, donor screening, product consistency and payer access are major commercial barriers.
  • The financial trajectory is likely determined by reimbursement and treatment-pathway adoption rather than by regulatory approval alone.

FAQs about Rebyota market potential and exclusivity

How much does Rebyota cost?

The publicly relevant commercial price depends on contracting, payer terms and administration fees. Ferring has not provided a publicly audited net-price figure that can be used as a universal market price.

Is Rebyota a live biotherapeutic product?

Rebyota is a fecal microbiota biological product containing live microorganisms derived from human stool. It differs from defined-strain live biotherapeutic products because its microbial composition is more complex.

Can Rebyota be substituted automatically at the pharmacy?

Automatic substitution is unlikely to operate like substitution for conventional small-molecule generics. Rebyota is administered rectally in a healthcare setting and is not an ordinary retail pharmacy product.

Does Vowst replace Rebyota?

Vowst is a direct competitor but does not automatically replace Rebyota. The choice depends on route preference, payer policy, clinical workflow and provider judgment.

Could a biosimilar of Rebyota enter before 2034?

A follow-on product could face substantial regulatory and manufacturing barriers. A separate microbiota product may enter without being a biosimilar, while the timing and applicability of a biosimilar pathway depend on FDA determinations.

References

  1. U.S. Food and Drug Administration. (2022, November 30). FDA approves first fecal microbiota product. https://www.fda.gov
  2. U.S. Food and Drug Administration. (2023, April 26). FDA approves first orally administered fecal microbiota product for prevention of recurrence of C. difficile infection. https://www.fda.gov
  3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov
  4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
  5. Ferring Pharmaceuticals. (2023). Rebyota prescribing information. https://www.rebyota.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.